TOP STORIES

• REGULATORY Japan to Introduce Fee Premium for Inpatient Biosimilar Use, Covering 13 APIs
  February 1, 2024

• BUSINESS Sumitomo to Cut Med- to Long-Term Guidance amid Tepid Uptake of New Drivers
  February 1, 2024

• REGULATORY Japan to Revise Ad Guidelines to Address GLP-1 Use for Cosmetic Weight Loss
  January 31, 2024

• COMMENTARY Is Case of Leqembi a “Steppingstone” to New CEA Price Adjustment Rule? Pharma Industry on Guard
  January 30, 2024

• REGULATORY MHLW to Require Pharma to Disclose More Categories of Physician Payments under Clinical Trials Act
  January 30, 2024

• REGULATORY Chuikyo to Discuss Exclusion of Long-Listed Biologics from New Coverage Scheme
  January 29, 2024

• REGULATORY Break-Up of LDP Factions Won’t Have Major Impact on Pharma Policy, but Could Make Lobbying Tougher
  January 26, 2024

• BUSINESS Towa Begins Priority Supply of 23 APIs, Mostly under Shipment Curbs, to Quake-Hit Area
  January 26, 2024

• ORGANIZATION JGA Chief Wary of “Full” Off-Year Revision in 2025, Urges Broader Exemptions If Plan Goes Forward
  January 25, 2024

• BUSINESS Ono Revs Up to Boost Global Presence, Launches New HR Scheme
  January 24, 2024

• COMMENTARY Goals of the “Innovation Box” Tax Break in FY2024 Reform
  January 23, 2024

• ACADEMIA Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi
  January 22, 2024

• BUSINESS LEO Pharma Poised to Build Presence in Japan as Dermatology Leader: CEO
  January 19, 2024

• REGULATORY Market Expansion Re-Pricing to Hit 23 Meds in April, Opdivo Faces Yet Another Cut in Spillover
  January 18, 2024

• BUSINESS Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
  January 18, 2024

• BUSINESS Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing
  January 18, 2024

• BUSINESS Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November
  January 17, 2024

• REGULATORY MHLW Issues Notification to Clarify Orphan Designation Criteria
  January 17, 2024

• COMMENTARY Introduction of Elective Care to Mark Watershed for Long-Listed Drug Makers
  January 17, 2024

• REGULATORY FY2024 Reform Will Bolster Rewards for Innovation to Eradicate Drug Lag/Loss: LDP Policy Bigwig
  January 16, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• …
• Next ›
• 最終 »